OssDsign AB (publ) (OSSD.ST)
SEK 10.08
(0.4%)
SEK 10.08
(0.4%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 83.64 Million SEK | 67.96% |
| 2022 | 45.13 Million SEK | 116.54% |
| 2021 | 20.84 Million SEK | 30.25% |
| 2020 | 16 Million SEK | 63.89% |
| 2019 | 9.76 Million SEK | -34.97% |
| 2018 | 15.01 Million SEK | 12.44% |
| 2017 | 13.35 Million SEK | 134.76% |
| 2016 | -38.41 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 12.08 Million SEK | -52.38% |
| 2024 Q2 | 27.7 Million SEK | 129.14% |
| 2023 Q4 | 25.38 Million SEK | 0.62% |
| 2023 FY | 75.8 Million SEK | 67.96% |
| 2023 Q1 | 18.14 Million SEK | 0.99% |
| 2023 Q2 | 20.97 Million SEK | 15.6% |
| 2023 Q3 | 25.23 Million SEK | 20.32% |
| 2022 Q3 | 12.97 Million SEK | 38.77% |
| 2022 Q2 | 9.35 Million SEK | 93.1% |
| 2022 FY | 45.13 Million SEK | 116.54% |
| 2022 Q4 | 17.96 Million SEK | 38.4% |
| 2022 Q1 | 4.84 Million SEK | -8.45% |
| 2021 FY | 20.84 Million SEK | 30.25% |
| 2021 Q4 | 5.29 Million SEK | -24.86% |
| 2021 Q3 | 7.04 Million SEK | 40.97% |
| 2021 Q2 | 4.99 Million SEK | 41.92% |
| 2021 Q1 | 3.51 Million SEK | -20.26% |
| 2020 Q4 | 4.41 Million SEK | -7.0% |
| 2020 Q3 | 4.74 Million SEK | 193.08% |
| 2020 FY | 16 Million SEK | 63.89% |
| 2020 Q1 | 5.22 Million SEK | 102.72% |
| 2020 Q2 | 1.61 Million SEK | -69.01% |
| 2019 Q1 | 2.22 Million SEK | -55.47% |
| 2019 FY | 9.76 Million SEK | -34.97% |
| 2019 Q4 | 2.57 Million SEK | -16.25% |
| 2019 Q3 | 3.07 Million SEK | 63.67% |
| 2019 Q2 | 1.88 Million SEK | -15.62% |
| 2018 Q3 | 3.43 Million SEK | 10.71% |
| 2018 Q2 | 3.1 Million SEK | -9.38% |
| 2018 Q1 | 3.42 Million SEK | 0.0% |
| 2018 FY | 15.01 Million SEK | 12.44% |
| 2018 Q4 | 5 Million SEK | 45.78% |
| 2017 FY | 13.35 Million SEK | 134.76% |
| 2016 FY | -38.41 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | -1479.101% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 72.174% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 72.174% |
| Arcoma AB | 11.07 Million SEK | -655.532% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | 40.245% |
| BICO Group AB (publ) | 1.83 Billion SEK | 95.431% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | 66.504% |
| CellaVision AB (publ) | 463.04 Million SEK | 81.936% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | -2690.958% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 394.379% |
| C-Rad AB (publ) | 66.01 Million SEK | -26.706% |
| Duearity AB (publ) | -4.17 Million SEK | 2102.034% |
| Dignitana AB (publ) | 58.97 Million SEK | -41.841% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 300.108% |
| Getinge AB (publ) | 13.43 Billion SEK | 99.377% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 266.566% |
| Iconovo AB (publ) | 17.57 Million SEK | -375.86% |
| Integrum AB (publ) | 690.56 Thousand SEK | -12012.598% |
| Luxbright AB (publ) | -2.79 Million SEK | 3090.658% |
| Mentice AB (publ) | 236.38 Million SEK | 64.614% |
| Paxman AB (publ) | 12.61 Million SEK | -562.902% |
| Promimic AB (publ) | 38.51 Million SEK | -117.175% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 264.808% |
| SciBase Holding AB (publ) | 16.03 Million SEK | -421.575% |
| ScandiDos AB (publ) | 47.55 Million SEK | -75.891% |
| Sectra AB (publ) | 557.55 Million SEK | 84.998% |
| Sedana Medical AB (publ) | 108.98 Million SEK | 23.248% |
| Senzime AB (publ) | 8.33 Million SEK | -903.058% |
| SpectraCure AB (publ) | -9.22 Million SEK | 1006.917% |
| Stille AB | 132.17 Million SEK | 36.715% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 95.771% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 79.937% |